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Abstract
Type 2 diabetes (T2D) is a complex disease characterized by beta cell dysfunctions. Islet amyloid polypeptide (IAPP) is
highly conserved and co-secreted with insulin with over 40% of autopsy cases of T2D showing islet amyloid
formation due to IAPP aggregation. Dysregulation in IAPP processing, stabilization and degradation can cause
excessive oligomerization with beta cell toxicity. Previous studies examining genetic associations of pathways
implicated in IAPP metabolism have yielded conflicting results due to small sample size, insufficient interrogation of
gene structure and gene-gene interactions. In this multi-staged study, we screened 89 tag single nucleotide
polymorphisms (SNPs) in 6 candidate genes implicated in IAPP metabolism and tested for independent and joint
associations with T2D and beta cell dysfunctions. Positive signals in the stage-1 were confirmed by de novo and in
silico analysis in a multi-centre unrelated case-control cohort. We examined the association of significant SNPs with
quantitative traits in a subset of controls and performed bioinformatics and relevant functional analyses. Amongst
the tag SNPs, rs1583645 in carboxypeptidase E (CPE) and rs6583813 in insulin degrading enzyme (IDE) were
associated with 1.09 to 1.28 fold increased risk of T2D (PMeta = 9.4610
23 and 0.02 respectively) in a meta-analysis of
East Asians. Using genetic risk scores (GRS) with each risk variant scoring 1, subjects with GRS$3 (8.2% of the cohort)
had 56% higher risk of T2D than those with GRS = 0 (P = 0.01). In a subcohort of control subjects, plasma IAPP
increased and beta cell function index declined with GRS (P = 0.008 and 0.03 respectively). Bioinformatics and
functional analyses of CPE rs1583645 predicted regulatory elements for chromatin modification and transcription
factors, suggesting differential DNA-protein interactions and gene expression. Taken together, these results support
the importance of dysregulation of IAPP metabolism in T2D in East Asians.
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Introduction
Type 2 diabetes (T2D) is characterized by abnormal beta cell
biology. Large scale genome-wide association studies (GWAS)
have discovered multiple loci associated with T2D in both
European [1] and Asian populations [2]. While some of these
risk variants independently conferred 1.1–1.5 fold increased risk,
this could increase to 2–3 folds in carriers with multiple genetic
variants [3]. Islet amyloid polypeptide (IAPP) is highly conserved
and co-secreted with insulin with suppressing effects on appetite
[4]. Over 40% of T2D autopsy cases in human showed amyloid
deposits associated with loss of beta cells [5]. IAPP is synthesized as
a prohormone (pro-IAPP) which is processed to mature IAPP in
endoplasmic reticulum (ER) by several enzymes and proteins,
including prohormone convertases (PCSK1, PCSK2), carboxy-
peptidase E (CPE) and serum amyloid P component (APCS)
before cleared by the insulin-degrading enzyme (IDE). Dysregu-
lation of these processing enzymes, increased stabilization of IAPP
by APCS and reduced clearance of IAPP by IDE [6,7,8] can lead
to accumulation of pro-IAPP or excessive oligomerization of IAPP
[9] which can cause mitochondrial dysfunction [10] and ER stress
[11]. Excessive pro-IAPP and IAPP production can also lead to
formation of amyloid beta sheet resulting in loss of islet structure
and beta cell function [9] (Figure S1).
Research studies including GWAS have revealed independent
associations of T2D with genetic polymorphisms of components of
IAPP metabolism [12,13,14]. However, these results were not
always consistent [15,16] due to small sample size, population
heterogeneity and incomplete interrogation of gene structure. The
hematopoietically expressed homeobox (HHEX)-IDE block is one of the
GWAS susceptibility loci for T2D with replications in multiple
ethnic groups [3,14]. Although HHEX is considered to be the most
likely causal gene in this block, some studies had shown
independent effect of genetic polymorphisms of IDE and their
combined effects with HHEX on risk of T2D [17].
In this report, we used a tag single nucleotide polymorphism
(SNP) approach to select genetic variants of candidate genes
(APCS, CPE, IAPP, IDE, PCSK1 and PCSK2) implicated in IAPP
metabolism (Figure S1) and tested their independent and joint
associations with risk of T2D and beta cell dysfunction. In this
multi-staged experiment, we performed de novo genotyping in 9,901
Asians and in silico analysis in 55,252 subjects followed by
bioinformatics and functional analyses (Table 1–3 and Figure 1–
3). The study design was summarized in Figure S2.
Results
Table S1 shows clinical characteristics of the study populations.
In the stage-1 study, 459 unrelated Chinese T2D patients and 419
age and sex-matched controls were included. Positive signals were
replicated in 3,092 Hong Kong Chinese (1,114 cases and 1,978
controls), 3,388 Shanghai Chinese (1,716 cases and 1,672
controls), 1,393 Korean (761 cases and 632 controls) and 1,150
Japanese (568 cases and 582 controls). The study cohorts of
Singaporeans and Europeans in in silico analysis were described in
Table S2.
We also examined the risk association of T2D in a family-based
cohort of Hong Kong Chinese consisting of 285 subjects with
diabetes and 187 without diabetes. In a subset of 85 control
subjects in whom IAPP and insulin were measured, we examined
the risk association of significant SNPs with beta cell function. In
the control subjects from the stage-1 study, we examined the
association of positive SNPs with quantitative traits function.
Stage-1 study
In the stage-1 study, we genotyped 89 single nucleotide
polymorphisms (SNPs) of the 6 target genes in 878 unrelated
cases and controls. Based on the HapMap Chinese data (CHB),
542 common SNPs in these genes were filtered for the tag SNP
selection. In addition to 7 reported SNPs, 135 SNPs were included
in the panel design with 89 SNPs finally selected for multiplex
genotyping with an average call rate of 95% and concordance rate
of 99.9% among the duplicate samples. Using these 89 SNPs, we
were able to capture 426 common SNPs, i.e. 79% of all common
SNPs with minor allele frequency (MAF) $0.05. Amongst these
SNPs, 4 SNPs [rs2808661 (APCS), rs12306305 and rs1056007
(IAPP), and rs4646953 (IDE)] failed quality control (QC) and were
excluded for analysis. All SNPs were in Hardy-Weinberg
equilibrium (HWE) (P.0.001 for controls). Table S3 shows the
Pallelic and Pempirical values for T2D of all SNPs, the latter generated
by 10,000 permutations under the best model of genetic models
for multiple test correction. Six of these SNPs showed nominal
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associations with 4 SNPs (rs1583645, rs6841638, rs10021007 and
rs17046561) in CPE, 1 SNP (rs6583813) in IDE and 1 SNP
(rs8117664) in PCSK2 with odds ratio (OR) and 95% confidence
intervals (CI) ranging from 1.24 (1.01–1.51) to 1.34 (1.02–
1.75)(Pempirical=0.01–0.05).
Stage-2 de novo genotyping
We replicated these 6 SNPs in 9,023 Asian subjects from Hong
Kong, Shanghai, Japan and Korea, with over 90% power to detect
ORs ranging from 1.24 to 1.34 at the 5% significant level. In the
Shanghai Chinese, rs6583813 was discarded due to unsuccessful
panel optimization and replaced by rs2149632 in a linkage
disequilibrium (LD) block with rs6583813 [r2 = 0.94; D’ = 1;
MAF=0.35 for both SNPs using HapMap CHB data]. Table 1
summarizes the results in each case-control cohort and meta-
analysis of stage-1 and 2 studies under allelic, dominant and
recessive models for each associated SNP. There were nominal
associations of T2D with rs1583645 and rs10021007 of CPE and
rs6583813 of IDE in at least one genetic model with some
population heterogeneity possibly due to sub-ethnicity and other
disease modifiers. For each SNP, we selected the most significant
genetic model and applied a fixed effect model for SNPs which did
not show heterogeneity of ORs (Q-statistic P.0.05). Otherwise, a
random effect model was used. In the combined analysis,
rs1583645 of CPE and rs6583813 of IDE were nominally
associated with T2D (PMeta = 0.001 and 0.045 respectively).
Joint effects of CPE and IDE genetic polymorphisms
We tested the joint effects of rs1583645 in CPE and rs6583813
in IDE on T2D risk in the Asian case-control cohort and beta cell
function in a subset of the Hong Kong Chinese controls. We
assigned each risk allele of rs1583645 (CPE) and rs6583813 (IDE)
as a genetic risk score (GRS) of 1 under additive models, which
was linearly associated with T2D risk (Pmeta = 0.01, Q-statistic
P,0.05 Figure 1) on meta-analysis. Subjects with the highest GRS
accounted for 8.2% of the study population and had 56% higher
risk for T2D compared to those with the lowest GRS (P=0.01). In
the control subjects of the Hong Kong cohort stratified by
GRS#1, 2 and$3 with similar numbers in each group, increasing
GRS was associated with progressive decline in Stumvoll’s index of
beta cell function (P=0.03) and area under the curve (AUC) of
insulin at 30-minute (P=0.05, Table 2). In the 472 subjects from
the Hong Kong family-based cohort, 85 non-diabetic unrelated
subjects had measurement of plasma IAPP levels. In these subjects,
the GRS was associated with increased plasma IAPP (P=0.008)
and IAPP to insulin (IAPP:INS) molar ratios (P=0.006) after
adjustment for age, sex, BMI and/or fasting insulin (Figure 2A and
2B).
In silico analysis in T2D GWAS studies and combined
meta-analysis
Having discovered and replicated the risk association of
rs1583645 of CPE and rs6583813 of IDE SNPs with T2D in
stage-1 and stage-2 experiments, we performed in silico analysis to
validate these findings in 2 GWAS. The Singapore cohort
consisted of 8,135 (3,781 cases and 4,354 controls) and the
European cohort, 47,117 subjects (8,130 cases and 38,987
controls) [18,19] (Table 3). In the Asian (CHB+JPK) and
European (CEU) HapMap database, the respective frequency of
the G allele of rs1583645 of CPE were 0.87 and 0.51 while that of
the C allele of rs6583813 of IDE were 0.39 and 0.68 (Table S4). In
the Caucasian population, we found strong association of IDE
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CPE. Due to this inter-ethnic differences, we only included de novo
genotyping and in silico analysis of GWAS data from the East Asian
populations and confirmed the risk association for CPE rs1583645
[OR:1.09(1.02–1.16), P=9.461023] in the fixed effect model and
IDE rs6583813 [OR:1.28(1.04–1.59), P=0.02] in the random
effect model.
Bioinformatics and functional analyses
Both CPE and IDE loci show mild conservation among species
and are located in the vicinity of regulatory elements for histone
modification, islet specific formaldehyde-assisted isolation of
regulatory elements (FAIRE) and DNaseI hypersensitive (HS)
peaks related to open chromatin modifications. A downstream
region from CPE rs1583645 is annotated with a CpG island and
pre-microRNA form (Table S5). Using transcription factor
binding site (TFBS) prediction tools, we identified 11 transcription
factors (TFs) which can either bind specifically to one or both of
these variants (Table S6). Due to its proximity to the promoter
region, we conducted functional tests on CPE rs1583645 variants
[G/A] using dual luciferase reporter assays transiently transfected
in HepG2 and rat INS-1E cells. In both cells transfected with the
constructs carrying the G-risk allele, the basal luciferase activity
was 50–66.7% higher than those transfected with A-allele of
rs1583645 [P,0.001 and P=0.005 respectively, Mann-Whitney
U-test (Figure 3)].
Discussion
In this multi-stage study, we used a hypothesis defined a priori
and a tag SNP approach combined with genetic statistics,
bioinformatics and functional analyses to examine the indepen-
dent and joint effects of components of the IAPP pathway on risk
of T2D and beta cell function. In the meta-analysis of de novo
genotyping and in silico analysis of GWAS data in Asian
populations, we confirmed the risk association of rs1583645 in
CPE and rs6583813 in IDE with T2D. Using GRS, we
demonstrated the joint effects of these two variants with increased
plasma IAPP and reduced beta cell function. These findings were
corroborated by bioinformatics analysis suggesting that the
flanking region of these SNPs might harbor regulatory elements
for gene expression through chromatin modification and binding
with TFs [20,21]. Results of luciferase activity assays indicated the
G risk allele was associated with lower CPE repression than the
non-risk allele which might cause dysregulation of IAPP produc-
tion and beta cell dysfunction.
In the genetic analysis, we used data from the HapMap Project
and selected tag SNPs which captured over 80% of common SNPs
with MAF$5% for each of these 6 candidate genes. The de novo
genotyping of unrelated case-control cohort consisting of 9,901
subjects had over 90% power to detect at least 20% increased risk
for T2D for SNPs with MAF of 10%. In the first stage experiment,
we selected 6 SNPs in CPE, IDE and PCSK2 which showed
nominal significance for replication. Notwithstanding some
heterogeneity of effect sizes possibly due to differences in
population-specific LD architecture, allele frequency [18] and
factors such as lifestyle and environment [22], rs1583645 of CPE
and rs6583813 of IDE showed consistent associations with T2D on
meta-analysis of multiple East Asian cohorts. Importantly, subjects
with $3 risk variants, which accounted for 8.2% of the study
population, had 56% increased risk of T2D. In the control
subjects, increased GRS was associated with increased plasma
IAPP and reduced insulin secretion. Taken together, these findings
support our hypothesis that dysregulation of IAPP pathway might
increase risk of beta cell dysfunction and T2D.
Insulin degrading enzyme (IDE)
Both CPE and IDE are widely expressed to process and degrade
different hormones including IAPP and insulin. In experimental
studies, inhibition of IDE decreased IAPP degradation and
increased IAPP toxicity while CPE mediated palmitate-induced
ER stress resulting in beta cell apoptosis [7,23,24]. These findings
were supported by association of variants of CPE and IDE with risk
of T2D and related traits in small cohort studies [25,26]. In
another study, rs2149632 of IDE was associated with reduced
insulin secretion [26,27]. In the stage-1 study, we selected reported
SNPs of IDE (rs4646953, rs4646958, rs1887922, rs4646957 and
rs2149632) but two of them failed during panel design of
genotyping and were replaced by their respective tag SNPs
(rs4304670 for rs4646957; rs6583813 for rs2149632). Amongst
these SNPs of IDE, only rs6583813 showed significance in the
Table 2. Associations of genetic risk scores (GRS) with beta cell function in Hong Kong Chinese unrelated controls (N = 419) with 1
risk allele of rs1583645 of CPE and rs6583813 of IDE each given 1 point.
Genetic risk score (GRS) 0-1 2 3–4 P value
Subjects (%) 30 41 29
Male (%) 42 38 36
Age (years) 41610 40611 40610
Body mass index (kg/m2) 22.563.2 22.663.3 22.563.1
Results of 75g oral glucose tolerance test
Fasting plasma glucose (mmol/l) a 4.8 (4.6,5) 4.72 (4.45,5.1) 4.8 (4.6,5.1) 0.88
Fasting plasma insulin (pmol/l)a 41.4 (26,60.7) 41.5 (25.2,54.1) 37.3 (24.1,56.7) 0.22
Plasma glucose at 30-minute (mmol/L)a 7.67 (6.68,8.75) 7.78 (6.85,8.87) 7.86 (6.89,8.61) 0.31
Plasma insulin at 30-minute (pmol/L)a 286 (180,449) 292 (182,427) 288 (196,407) 0.24
Glucose AUC at 30-minute (min.mmol/l)a 195 (179,205) 190 (175,207) 191 (177,210) 0.73
Insulin AUC at 30-minute (min.pmol/l)a 5817 (3583,7811) 5670 (3555,8432) 4856 (3574,6922) 0.05
Stumvoll’s index of beta cell function (61026)a 29.7 (21.7,40.7) 30.8 (19.8,42.8) 27.1 (18.4,36.1) 0.03
Data were shown as mean6SD or amedian(interquartile range) and analyzed by the linear regression with adjustment of age, sex and BMI under additive models after
log-transformation. P values in bold indicated significance for the phenotypes. AUC: area under the curve.
doi:10.1371/journal.pone.0062378.t002
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stage-1 study and was replicated in later stages using additional
cohorts. In a GWAS examining risk variants for multiple diseases
in Icelanders, our group contributed to the discovery of the risk
association of T2D with rs1111875 which lies in the intergenic
region of the HHEX-IDE LD locus [28]. This SNP has now been
validated in multiple cohorts albeit with inter-ethnic differences in
allele frequency and effect size [3,29,30]. Other researchers have
reported the close proximity of this SNP with highly conserved
non-coding elements which may control expression of TFs [31].
The importance of this HHEX-IDE block was further supported by
the joint effects of TCF7L2, HHEX and IDE on risk of T2D [17].
In the present analysis, the SNP discovered in our study,
rs6583813, was located near the 39 end of IDE with a moderate
LD (r2 = 0.67 in Hong Kong Chinese) with rs1111875. Although
we cannot be absolutely certain about the independent effect of
rs6583813, in a recent epigenome study of human pancreatic
islets, this novel SNP was found to lie within a putative regulatory
element (NCBI Build 36.1 CHR10:94,199,479–94,203,011) im-
plicated in epigenetics [21].
Table 3.Meta-analysis of risk associations of CPE rs1583645 and IDE rs6583813 with Type 2 diabetes (T2D) using data from de novo
genotyping and in silico analysis in a multi-ethnic population.
Risk Allele
CHR:bp in Number Frequency
SNP Gene NCBI Build 36.1 Allelesa Study Cases Controls Cases Controls OR trend(95% CI)P trend
rs1583645 CPE CHR4:166,517,901 G/A Stage-1
Hong Kong Chinese 410 386 0.770 0.727 1.26(1–1.58) 0.049
Stage-2 denovo replication
Hong Kong Chinese 1079 1969 0.788 0.756 1.20(1.06–1.36) 5.2461023
Shanghai Chinese 1618 1634 0.861 0.841 1.18(1.02–1.35) 0.021
Korean 754 629 0.847 0.866 0.86(0.69–1.06) 0.161
Japanese 568 582 0.873 0.863 1.00(0.79–1.27) 0.993
Stage-3 in silico analysis
Singapore Chinese 2009 1945 0.800 0.799 1.00(0.89–1.12) 1.00
Singapore Malay 1235 792 0.65 0.62 0.88(0.77–1.00) 0.06
Singapore Indian 1166 971 0.66 0.65 0.96(0.84–1.09) 0.52
DIAGRAM+ 38987 8130 b0.51 – 1.00(0.96–1.04) 0.92
cMeta-analysis in Asian
subjects
Fixed effect 1.09(1.02–1.16) 9.461023
Random effect 1.01(0.85–1.2) 0.898
Heterogeneity test P= 0.05
rs6583813 IDE CHR10:94,199,919 C/T Stage-1
Hong Kong Chinese 429 414 0.364 0.315 1.23(1.01–1.49) 0.042
Stage-2 denovo replication
Hong Kong Chinese 1076 1952 0.342 0.346 0.98(0.88–1.1) 0.754
Shanghai Chinese 1292 1576 0.292 0.297 0.98(0.88–1.09) 0.708
Korean 756 630 0.40 0.344 1.27(1.08–1.48) 3.061023
Japanese 568 582 0.399 0.296 1.58(1.32–1.88) 3.4361027
Stage-3 in silico analysis
Singapore Chinese 1935 1879 0.315 0.278 1.20(1.09–1.33) 4.061024
Singapore Malay 1188 759 0.28 0.30 1.07(0.93–1.24) 0.34
Singapore Indian – – – – – –
DIAGRAM+ 38987 8130 b0.68 – 1.17(1.12–1.22) 1.33610212
cMeta-analysis in Asian
subjects
Fixed effect 1.23(1.14–1.34) 8.2561027
Random effect 1.28(1.04–1.59) 0.02
Heterogeneity test P= 0.002
aRisk alleles were underlined. bThe allele frequency was based on HapMap Caucasian (CEU) population. cMeta-analysis for the Chinese from Hong Kong, Shanghai.
and Singapore, Korean and Japanese cohorts.
doi:10.1371/journal.pone.0062378.t003
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Carboxypeptidase E (CPE)
Regulation of gene expression (epigenetics) is a complex process
involving chromatin and histone modifications which play pivotal
roles in determining cellular structure and function [20,21,32]. In
a recent epigenetic study on islet cells, CPE is one of the reported
genes contained in an islet-selective open chromatin [20] which
encompasses various gene regulatory elements. Despite their
upstream locations from the promoter and transcription start site,
these elements recruit TFs to form a DNA loop to bring them into
interactions with promoter to regulate gene expression [33]. Our
results indicated that CPE variants at rs1583645 exhibited
differential transcriptional activity, suggesting that they might
alter gene expression via DNA-protein interactions. On bioinfor-
matics analysis, 11 TFs were predicted to bind to either one or
both variants [G/A]. While these predictions need experimental
confirmation, two of these TFs, upstream stimulating factor (USF)
which binds to the G-allele and octamer binding factor 1 (Oct1 also
known as POU2F1) which binds to the A-allele of CPE, are located
within the chromosome 1q region which is the most replicable loci
for T2D in multiple populations [34]. Besides, we have reported
risk association of T2D in our Chinese populations with variants of
USF and POU2F1 [35], the latter also known to interact with
histone proteins to alter chromatin organization and inflammatory
responses [36].
IAPP and insulin
In our family-based association test (FBAT) analysis, none of the
SNPs of CPE or IDE showed associations with T2D, possibly due
to small sample size and young age of the subjects. However, in
this family-based cohort, non-diabetic subjects with high GRS had
increased plasma IAPP and IAPP to insulin (IAPP:INS) ratio. In
experimental studies, high IAPP, either de novo or compensatory,
can induce ER stress and trigger apoptotic signaling pathways with
increased expressions of C/EBP homologous proteins (CHOP)
and caspase-3 [37]. In in vitro studies, we have demonstrated beta
cell toxicity associated with IAPP oligomerization due to
mitochondrial dysfunction and oxidative stress [9,10].
Figure 1. Based on results of a meta-analysis of risk association of type 2 diabetes (T2D) in 9,901 Asian subjects with de novo
genotyping, each risk allele of rs1583645 (CPE) and rs6583813 (IDE) was given a genetic risk scores (GRS) of 1 under additive
models. Increasing GRS was associated with increasing trend of risk for T2D (Pmeta = 0.01; Q-statistic P,0.05) with the highest GRS of 4 conferring an
odds ratios of 1.56 compared to the lowest GRS of 0 (*P=0.01).
doi:10.1371/journal.pone.0062378.g001
Figure 2. Plasma IAPP (A) and molar ratio of IAPP to insulin
(IAPP/INS) (B) in 85 unrelated non-diabetic controls selected
from a family-based cohort categorized by genetic risk scores
(GRS) (1 risk allele of rs1583645 of CPE and rs6583813 of IDE
each given 1 point). Plasma IAPP (*P= 0.008) and IAPP/INS ratio
(**P= 0.006) increased with increasing GRS.
doi:10.1371/journal.pone.0062378.g002
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Insulin and IAPP form complexes in secretory granules and are
secreted in a fixed ratio. However, subject to different stimuli or
conditions, these peptides may exhibit different kinetics and
responses. Both insulin and IAPP share similar transcriptional
regulators and enzymatic pathways for maturation and degrada-
tion [38,39]. Thus, reduced CPE activity may lead to low insulin
response with compensatory increase of pro-IAPP or alternatively,
high CPE activity may increase IAPP production. Both scenarios
can potentially lead to beta cell toxicity due to excessive
oligomerization especially in the presence of reduced IAPP
clearance. In experimental studies, exposure to fatty acids induced
overexpression of IAPP resulting in impaired insulin secretion
[40]. Thus, genetic or acquired factors which perturb activities of
these processing and degrading enzymes may alter IAPP:INS ratio
to increase risk of IAPP oligomerization, fibril formation, beta cell
dysfunction and T2D [41]. Without measuring CPE and IDE
activity, the final effects of these functional SNPs remain
uncertain, although the multiple associations between GRS and
risk of T2D, reduced beta cell function and increased IAPP
support the functional significance of these variants and our
overall hypothesis.
Study limitations
Although the combined cohort of 9,901 subjects had over 90%
power to detect at least 20% increased risk of T2D for SNPs with
MAF$0.05, our first stage study involving 459 young patients with
familial T2D and 419 controls might have excluded some SNPs
with low MAF or effect size resulting in type 2 error. Analysis of
these SNPs in a larger sample size will be needed to ascertain their
associations with risk of T2D. To overcome possible type 1 error,
we performed 10,000 permutation tests to adjust for multiple
comparisons. In the quantitative trait analysis, the IAPP results
might be confounded by cross-reactivity of the IAPP antibody with
pro-IAPP. Although the genetic and bioinformatics analysis on
rs1583645 and rs6583813 of CPE and IDE support their functional
significance, further studies are needed to examine their effects on
IAPP, insulin and/or other substrates. Finally, effects due to
adjacent variants via LD structures with stronger causal relation-
ships cannot be excluded.
Conclusion
In this study, we combined our understanding of the IAPP
pathway with genetic analysis and used multiple cohorts to
demonstrate the genotype-phenotype correlations relevant to T2D
and beta cell function. Using a hypothesis driven approach, we
confirmed the risk association of T2D with SNPs in CPE and IDE.
In non-diabetic subjects, these risk variants were associated with
reduced beta cell function, increased IAPP levels and IAPP:INS
ratio. Bioinformatics and functional analyses suggested that these
SNPs are located within regulatory sites for DNA-protein binding.
Although the effect size of these SNPs averaged 15–20%, they can
be found in 5% to 50% of the population. It has been estimated
that for complex diseases such as T2D, 50% of population
attribution risks can be explained by 20 or fewer susceptibility
genes with an effect size of 10–20% [42]. Taken together, our
findings support the important roles of IAPP processing and
Figure 3. Effect of rs1583645 [G/A] polymorphism on luciferase activity assays. (A) Upstream region of transcription start site (TSS as
indicated by the black arrow), first exon and part of intron 1 of CPE (NCBI Build 36.1, CHR4:166,496,501–166,536,501). The LD structure of CPE SNPs
within this region was shown by D’ using the Chinese HapMap data. The red arrow indicated the location of rs1583645. (B) CPE-[G/A] constructs
consisting of 449 bp of CPE rs1583645 region and pGL4.23 firefly luciferase reporter vectors were transfected into HepG2 (left panel) and rat INS-1E
cells (right panel) together with Renilla luciferase reporter vectors. Measurement of the firefly luciferase activity of CPE-[G/A] constructs was
normalized relative to the activity of the Renilla luciferase vectors. Data were shown as mean6SEM of at least three independent experiments in
triplicate set up. The constructs of CPE-G showed 50% and 66.7% increased transcriptional activity in HepG2 and rat INS-1E cells respectively when
compared to the constructs of CPE-A (P,0.001 and P=0.005 respectively by Mann-Whitney U-test).
doi:10.1371/journal.pone.0062378.g003
Genetic Variations of IAPP Pathways and T2D
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e62378
degrading enzymes in T2D and that a multi-staged approach
using tag SNPs of candidate genes within a biological pathway
may discover novel variants to identify high risk subjects for T2D.
Methods
Recruitment of samples
Stage-1 study. In the stage-1 study, we selected 459 T2D
subjects diagnosed before 40 year-old who had at least one affected
first degree relative from the Hong Kong Diabetes Registry
(HKDR) [43]. None of these patients had clinical or autoimmune
type 1 diabetes, defined as history of ketoacidosis or continuous
requirement of insulin within 1 year of diagnosis with or without
autoimmune antibodies. Another 419 control subjects with normal
glucose tolerance (NGT) [fasting plasma glucose (FPG),6.1
mmol/L] and no family history of diabetes were recruited from
community-based health screening programs [44].
De novo and in silico replication
In the stage-2 study, we included case-control cohorts consisting
of 3,564 Hong Kong Chinese 3,388 Chinese from Shanghai, 1,393
Koreans and 1,150 Japanese [3,45,46]. We also performed the
FBAT analysis in 472 subjects recruited from the Hong Kong
Diabetes in Family Study [47]. All participants were recruited as
part of a diabetes gene discovery program in respective countries.
In the stage-3 study, we performed in silico replication in 2 GWAS
conducted in Singaporean and European populatioins including
3,955 Chinese (2,010 cases, 1,945 controls), 2,034 Malays (794
cases, 1,240 controls) and 2,146 Indians (977 cases, 1,169 controls)
and 47,117 Europeans (8,130 cases and 38,987 controls) (Text S1,
Table S1 and S2).
Tag SNP selection
Using the HapMap Phase II database for Han Chinese from
Beijing (www.hapmap.org), all SNPs with MAF$0.05 in six
candidate genes with ,2 kb flanking regions were selected. Their
pair-wise LD was estimated in terms of r2 by Haploview v 4.0RC2
[48]. Under a pair-wise tagging mode with r2$0.8, 82 tag SNPs
were selected. Together with 7 SNPs reported to be associated
with T2D and/or related traits (rs4646953, rs4646958, rs1887922,
rs4646957 and rs2149632 in IDE; rs2808661 and rs6689429 in
APCS) [15,27,49], 89 SNPs were selected in the stage-1 study for
genotyping in 459 cases and 419 controls. Nominally significant
SNPs for T2D were replicated in stage-2 and stage-3 studies.
Genotyping
In the stage-1 study, all SNPs were genotyped using the matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF)
MassARRAY System (Sequenom, San Diego, CA) at the Genome
Research Center at the University of Hong Kong or Genome
Quebec Innovation Center at the McGill University. Each of 96
well plates contained negative controls and duplicate samples for
QC. Only SNPs with genotyping call rates$0.8, MAF$0.05 and
exhibiting no departure from HWE in control subjects (P.0.001)
were included for analysis. Stage-2 genotyping was performed
using either Sequenom’s MassARRAY System (Sequenom, San
Diego, CA) or the MGB TaqMan Assay (Applied Biosystems,
Foster City, CA, USA).
Clinical assessment and metabolic profiling
All patients enrolled in the HKDR [43] underwent structured
assessments modified from the European Diabcare protocol [50].
In brief, the HKDR was established in 1995 and enrolls 30–50
ambulatory diabetic patients per week. Patients were referred by
general practitioners and internists from community and hospital-
based clinics or were discharged from the Prince of Wales Hospital
or other regional hospitals. All patients underwent a comprehen-
sive diabetes assessment with documentation of detailed pheno-
types and clinical outcomes to form the HKDR. All control
subjects underwent detailed clinical examination. A subset
(N= 302) of control subjects underwent 75g oral glucose tolerance
tests (OGTT) and blood samples were collected at multiple time-
points for plasma glucose (PG) and insulin measurements. PG
assayed enzymatically using the Roche Modular Analytics system
(Roche Diagnostics GmbH, Mannheim, Germany). Insulin was
assayed using the enzyme-linked immunosorbent assays (Dako-
Cytomation, Cambridgeshire, UK). The precision of these assays
was within that specified by the manufacturer. In the family-based
cohort involving 472 subjects (285 cases, 187 controls), a random
subcohort of 85 subjects with normal glucose tolerance had
measurement of fasting plasma IAPP determined in the laboratory
of Professor Garth JS Cooper using a radioimmunoassay method
with an inter-assay coefficient of variation (CV) of 3.5% [51].
Calculation
The AUC of PG and insulin during OGTT was calculated by
the trapezoid rule. Insulin resistance (HOMA-IR) was calculated
by the equation of [fasting insulin (mU/l)6 fasting PG (mmol/l)
422.5] while beta cell function was estimated by two algorithms:
1) HOMA-b = [fasting insulin (mU/l)6204 (fasting PG (mmol/
l)-3.5)] and 2) Stumvoll’s index of beta cell function (61026) =
[insulin AUC30min (min.pmol/l) 4 glucose AUC30min (min.mmol/
l)] [52].
Bioinformatics and functional analyses
We tracked the University of California, Santa Cruz (UCSC)
human genome browser (http://genome.cse.ucsc.edu/cgi-bin/
hgGateway) to examine the cross-species conservation and
regulatory elements including CpG islands, chromatin structure
and histone modification sites within the flanking regions of
rs1583645 in CPE and rs6583813 in IDE (NCBI Build 36.1
CHR4:166,517,651–166,518,151 and CHR10:94,199,669–
94,200,169 respectively). We also performed TFBS prediction
using the MATCHTM program [53].
Transient transfection studies
We generated two clones with identical sequences except [G/A]
variants at rs1583645 of CPE into pGL4.23 vectors (Promega) by
PCR cloning and QuickChange Site-Directed Mutagenesis Kit






mutation underlined). We independently transfected these clones
with Renilla luciferase vectors [pGL4.73(hRluc/SV40)] into
HepG2 and rat INS-1E cells using LipofectamineTM 2000
(Invitrogen). Empty pGL4.23 vectors were included as reference
for comparisons. Next, we detected their luciferase activities in
cells with different variants in at least 3 independent experiments
using the Dual-Luciferase Reporter Assay kit (Promega) in
accordance to the manufacturer’s instructions.
Statistical analysis
All data were expressed as mean6SD or median (interquartile
range) as appropriate. Skewed data were transformed using
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natural logarithms and outlier data ($ or #4SD from the mean)
were excluded. All statistical tests were performed by PLINK
(v.1.07 http://pngu.mgh.harvard.edu/,purcell/plink), Haplo-
view (v 4.0RC2 http://www.broad.mit.edu/mpg/haploview) or
Stasticial Package for Social Sciences (vereson 15.0) for Windows
(SPSS Inc., Chicago, IL, USA) unless specified otherwise. The
study power in allelic models was estimated using PASS 2008
(NCSS, LLC. Kaysville, Utah). Assuming allelic models, our
samples had over 90% power to detect at least 20% increased risk
for T2D for SNPs with MAF of 0.1 and a of 0.05. The SNPs
which passed QC were analyzed in each study cohort by the x2
and logistic regression (LR) analysis under allelic, dominant and
recessive models with or without adjustments. To adjust for
multiple testings in stage-1 study, we also presented empirical P
values by 10,000 permutations under the most significant models
implemented by PLINK, which was used to select SNPs for
replication.
Except for stage-1 experiment, 2-tailed P values,0.05 were
considered statistically significant in allelic, dominant and/or
recessive models unless specified otherwise. Risk association
was expressed as OR with 95% CI. We selected the best model
based on P values among genetic models for the meta-analysis
of T2D in the combined cohort. The latter was performed by
the Cochran-Mantel-Haenszel (CMH) test implemented in
PLINK to estimate the combined ORs, 95% CI and
significance level, using study population as a strata. Hetero-
geneity of ORs was assessed by the Cochran’s Q statistic which
was calculated as the weighted sum of squared differences
among individual study effects and the pooled effect across
studies. In case of significant heterogeneity (Q-statistic
P,0.05), the effect size calculated from the model for random
effects was also reported [54]. For the analysis of family-based
cohort, Mendelian errors and potential genotyping errors were
checked by PEDCHECK (v.1.1; http://watson.hgen.pitt.edu)
and removed accordingly. We used the FBAT (v.2.0.3; http://
www.biostat.harvard.edu/,fbat) based on the transmission
disequilibrium test (TDT) but generalized to allow analysis in
additive models of inheritance using –e option for testing the
null hypothesis of ‘‘no linkage and no association’’. The power
was estimated by FBAT [55] assuming a disease prevalence of
10%, additive models with allelic OR of 1.2 for SNP with MAF
of 0.1.
To test the joint effects of significant SNPs, we assigned a score
of 1 to each risk allele to generate GRS with a maximum of 4 in
combined analysis of cohorts with de novo genotyping. We also
applied linear regression analysis to test the effects of GRS with
beta cell function in subsets of control subjects with adjustment for
covariates, as appropriate. For the dual luciferase reporter assays,
all experiments were performed using a triplicate set-up consisting
of 3 independent tests. All results were expressed as mean6SEM
and Mann-Whitney U-test was used to compare differences
between groups.
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